This site is intended for healthcare professionals
News

Health Canada approves Rybelsus to treat type 2 diabetes.- Novo Nordisk

Read time: 1 mins
Last updated:24th Sep 2021
Published:15th Apr 2020
Health Canada has approved Rybelsus (semaglutide tablets) from Novo Nordisk as a treatment option to improve glycemic control in adults with type 2 diabetes mellitus, along with diet and exercise. Rybelsus is the first and only glucagon-like peptide-1 (GLP-1) analogue available in a tablet and is indicated as a monotherapy when metformin is considered inappropriate due to intolerance or contraindications. Rybelsus can be used in combination with other medicinal products for the treatment of type 2 diabetes in adults. Rybelsus will be available in pharmacies across Canada beginning April 27, 2020.
Condition: Diabetes Type 2
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.